Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.Materials and Methods We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.Results Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).Conclusion In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.
Abstract
Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.Materials and Methods We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.Results Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).Conclusion In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.
참고문헌 (21)
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Vitolo U, "Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma", J Clin Oncol, 35, pp.3529~3537 (2017)
- Bartlett NL, "Dose-adjusted EPOCH-R compared with RCHOP as frontline therapy for diffuse large B-cell lymphoma : clinical outcomes of the phase III intergroup trial alliance", CALGB 50303, 2019, pp.37, 1790~1799
- Nowakowski GS, "ROBUST : a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma", J Clin Oncol, 39, pp.1317~1328 (2021)
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project, "A predictive model for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 329, pp.987~994 (1993)
- Schmitz R, "Genetics and pathogenesis of diffuse large B-cell lymphoma", N Engl J Med, 378, pp.1396~1407 (2018)
- Gisselbrecht C, "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era", J Clin Oncol, 28, pp.4184~4190 (2010)
- Hamadani M, "Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation", Biol Blood Marrow Transplant, 20, pp.1729~1736 (2014)
- Crump M, "Outcomes in refractory diffuse large B-cell lymphoma : results from the international SCHOLAR-1 study", Blood, 130, pp.1800~1808 (2017)
- Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
- Salles G, "Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma(L-MIND) : a multicentre, prospective, single-arm, phase 2 study", Lancet Oncol, 21, pp.978~988 (2020)
- Sehn LH, "Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma", J Clin Oncol, 38, pp.155~165 (2020)
- Hutchings M, "Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial", J Clin Oncol, 39, pp.1959~1970 (2021)
- Kim SJ, "Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma : results of a multicenter prospective cohort study", Oncotarget, 7, pp.72033~72043 (2016)
- Hyun JS, "A prospective registry study of Peg-G-CSF prophylaxis for patients with diffuse large B-cell lymphoma(CISL 1403)", Blood, 130(Suppl 1), pp.2840~ (2017)
- Swerdlow SH, "WHO classification of tumours of the haematopoietic and lymphoid tissues" (2008), IARC Press
- Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Vannata B, "Late relapse in patients with diffuse large B-cell lymphoma : impact of rituximab on their incidence and outcome", Br J Haematol, 187, pp.478~487 (2019)
- Epperla N, "Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation", Blood Adv, 3, pp.1661~1669 (2019)
- Wang S, "Outcomes in refractory diffuse large B-cell lymphoma : results from a multicenter real-world study in China", Cancer Commun(Lond), 41, pp.229~239 (2021)